Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UCAR-T cell therapy targeting HER2 or EGFR
- Development stage
- Unknown
- Lead developer
- Zhongshan People's Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
UCAR-T cell therapy targeting HER2 or EGFR is an allogeneic, 'off-the-shelf' chimeric antigen receptor (CAR) T-cell therapy developed by Zhongshan People's Hospital. It is designed to target either Human Epidermal Growth Factor Receptor 2 (HER2) or Epidermal Growth Factor Receptor (EGFR), both of which are frequently overexpressed in high-grade gliomas. As a 'universal' CAR-T (UCAR-T) product, it is derived from healthy donor cells and engineered to minimize graft-versus-host disease (GvHD) and host rejection, allowing for immediate availability without the need for patient-specific manufacturing. The therapy is currently being evaluated in a Phase 1 clinical trial (ChiCTR2200059343) for patients with advanced, relapsed, or refractory high-grade glioma to assess its safety, tolerability, and preliminary efficacy.
- Other names
- UCAR-T cell injection targeting HER2 or EGFR
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on UCAR-T cell therapy targeting HER2 or EGFR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UCAR-T cell therapy targeting HER2 or EGFR.